In 2025, the psychedelic medicine sector reached a more defined phase of maturity, as Big Pharma entry, late-stage clinical readouts,...
Psilocybin continues to gain momentum as a possible alternative to mental health treatments that leave large numbers of patients without recovery.
Compass Pathways is one of the companies spearheading clinical development of synthetic psilocybin, the compound naturally found in psilocybin mushrooms.
A new study in The Journal of Neuroscience has shed light on how the psychedelic N,N-Dimethyltryptamine, or DMT, changes brain activity during its most intense psychological...
On 4 December 2025, London’s Conway Hall will host the third PSYCH Symposium, bringing together leaders across science, policy, investment and clinical medicine to chart the...
Ambio Life Sciences, a company known for its physician-led ibogaine therapy programmes, has been thrust into the global spotlight with the release of In Waves and...
A newly published systematic review titled on psilocybin’s effects on obsessive‑compulsive behaviours provides an up-to-date synthesis of research into the compound’s potential for treating OCD and...
Last week, the U.S.
Arcadia Medicine, a San Francisco-based biotech startup developing MDMA-like empathogens, this month closed roughly $9.25 million in seed financing and won FDA clearance to begin human...
Dr. Celia Morgan is one of the UK’s leading figures in ketamine and psychedelic research, especially in the domain of addiction and mental health.
